Eli Lilly vs. Novo Nordisk: The High-Stakes Battle for the Weight-Loss Pill Market

NEW YORK – The race to dominate the global weight-loss industry has moved from injections to oral medication, as Eli Lilly’s new pill, Foundayo, faces its first major test against market leader Novo Nordisk. Recent data shows a competitive struggle for market share as patients increasingly look for easier alternatives to weight-loss shots.

The Numbers Game: Foundayo’s Market Debut

In its fourth week of availability in the U.S., Foundayo saw 7,335 prescriptions filled. While this indicates a growing interest, it remains a modest start compared to Novo Nordisk’s Wegovy pill, which benefited from a “first-mover advantage” after its January launch.

However, Eli Lilly executives remain optimistic, reporting that over 20,000 patients have already begun treatment and that the drug is attracting a new wave of doctors. Surprisingly, a third of the 8,000 prescribers for Foundayo had never before prescribed an oral GLP-1 medication, suggesting the market is expanding beyond traditional obesity specialists.

Investor Expectations and Revenue Targets

Wall Street is keeping a close eye on the weekly “script” data. To meet the second-quarter sales target of $160 million, analysts from RBC Capital Markets suggest that Foundayo will need to scale up to approximately 22,000 prescriptions per week shortly.

The industry believes that these next-generation pills will revolutionize the market by:

• Providing a needle-free option for millions of needle-phobic patients.

• Lowering the logistical costs associated with refrigerated injections.

• Countering the pricing pressures currently facing the weight-loss drug sector.

Telehealth: The New Frontier for Weight Loss

A significant portion of Foundayo’s launch volume—roughly 35%—is being driven by telehealth platforms. With more than 12 major telehealth firms now offering the pill, access is easier than ever. Eli Lilly has also integrated the drug into its LillyDirect platform to streamline shipping and prescriptions directly to consumers.

While current data from trackers like IQVIA shows some fluctuations due to gaps in telehealth reporting, the trend is clear: the demand for effective, oral weight-loss solutions is at an all-time high, and the competition between pharmaceutical giants is only just heating up.